Kinnate Biopharma will be the majority shareholder in the joint venture.
- Kinnate Biopharma will be the majority shareholder in the joint venture.
- KIN-2787 is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor candidate being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.
- The joint venture will also pursue development of KIN-3248 for the Chinese market.
- Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.